CEVEC and UCB sign agreement for the use of CEVEC’s ELEVECTA® AAV manufacturing technology in Gene Therapy

  • The ELEVECTA® Technology produces Stable Producer Cell Lines designed to enable fully scalable, high-performance AAV vector production
  • Under the agreement, CEVEC grants UCB rights and options to the ELEVECTA® Technology for the research, development and manufacturing of AAV gene therapy products

Cologne, Germany, September 7, 2021


Subscribe for the CEVEC Newsletter according to our Privacy Policy to receive the latest CEVEC News, including Press Releases, Conference Information and Webinar Invitations.

© CEVEC Pharmaceuticals GmbH 2021